Dividend On Watch: Dec 15, 2016 will be the day that Atrion Corporation (NASDAQ:ATRI) dividends reach $1.05.

Dividend On Watch: Dec 15, 2016 will be the day that Atrion Corporation (NASDAQ:ATRI) dividends reach $1.05.

Atrion Corporation (NASDAQ:ATRI) is expected to pay $1.05 on Dec 15, 2016. The indicated annual dividend is $4.20. Shareholders owning the stock before Nov 29, 2016 will be eligible to receive the payout. Based on Atrion Corporation’s current price of $488.65, the dividend is 0.21%. This dividend’s record date is Dec 1, 2016 and the announcement date is Nov 11, 2016. The stock increased 0.91% or $4.4 on November 25, hitting $488.65. Atrion Corporation (NASDAQ:ATRI) has risen 22.32% since April 25, 2016 and is uptrending. It has outperformed by 16.31% the S&P500.

Atrion Corporation is engaged in developing and manufacturing products, primarily for medical applications. The company has a market cap of $887.17 million. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. It has a 32.27 P/E ratio. The Company’s fluid delivery products include valves that promote infection control and needle safety.

Insitutional Activity: The institutional sentiment increased to 0.94 in 2016 Q2. Its up 0.23, from 0.71 in 2016Q1. The ratio is positive, as 6 funds sold all Atrion Corporation shares owned while 49 reduced positions. 11 funds bought stakes while 28 increased positions. They now own 951,213 shares or 2.74% less from 978,001 shares in 2016Q1.
Price T Rowe Associates Md has invested 0.02% of its portfolio in Atrion Corporation (NASDAQ:ATRI). Stifel Financial holds 1,875 shares or 0% of its portfolio. Ny State Common Retirement Fund holds 0% of its portfolio in Atrion Corporation (NASDAQ:ATRI) for 1,600 shares. Amer last reported 784 shares in the company. Bancshares Of Montreal Can holds 316 shares or 0% of its portfolio. Northern holds 0% or 18,547 shares in its portfolio. Tower Cap Ltd Liability Corporation (Trc) last reported 205 shares in the company. Geode Capital Mgmt Lc has invested 0% of its portfolio in Atrion Corporation (NASDAQ:ATRI). Wilen Investment Mgmt accumulated 476 shares or 0.13% of the stock. Bancorporation Of America De, a North Carolina-based fund reported 2,184 shares. Neuberger Berman Gru Ltd Llc holds 0.02% of its portfolio in Atrion Corporation (NASDAQ:ATRI) for 34,325 shares. Barclays Public owns 6 shares or 0% of their US portfolio. Pdt Ptnrs Ltd Liability Company owns 700 shares or 0.02% of their US portfolio. Pnc Services Grp Inc holds 1,130 shares or 0% of its portfolio. D E Shaw & Co has 0% invested in the company for 967 shares.

Insider Transactions: Since June 15, 2016, the stock had 0 insider buys, and 6 sales for $4.42 million net activity. The insider BATTAT EMILE A sold $947,849. 784 shares were sold by STEBBING ROGER F, worth $350,164 on Friday, August 12. MORGAN HUGH J JR also sold $891,476 worth of Atrion Corporation (NASDAQ:ATRI) on Monday, August 29.

More news for Atrion Corporation (NASDAQ:ATRI) were recently published by: Seekingalpha.com, which released: “Atrion Corporation: Is It A Worthy Investment For The Long Term?” on March 20, 2015. Seekingalpha.com‘s article titled: “Atrion Corporation: Not Quite A Bargain, But A Company Investors Should Keep …” and published on November 07, 2014 is yet another important article.

ATRI Company Profile

Atrion Corporation (Atrion), incorporated on December 30, 1996, is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. The Company’s fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in areas, such as anesthesia and oncology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment